- Nurocor, founded in 2017 and based in Austin, Texas, develops a cloud-based clinical platform designed to accelerate drug development processes for pharmaceutical companies, positioning itself as a leader in digitalized clinical development.
- In July 2025, Nurocor raised $1 million in a venture capital round led by Simulations Plus to expand its operations and enhance its development efforts.
- Nurocor has formed a strategic partnership with Bristol Myers Squibb to leverage AI innovations in clinical development, showcasing its commitment to advancing the life sciences sector.
- Nurocor's ideal buyers are pharmaceutical companies seeking to improve efficiency and reduce time-to-market for drug development, addressing critical pain points in clinical trial management.
Nurocor's workforce is organized into five departments, with a total headcount of 34 employees. The largest department is Information Technology, comprising 10 employees, followed closely by Engineering with 9 employees. Operations, Executive, and Other departments contribute to the functional balance, with 7, 4, and 6 employees respectively. This distribution indicates a strong emphasis on technical capabilities while maintaining essential operational and executive support.
Nurocor operates across nine locations, with a notable concentration in Austin, Texas. The company maintains a distributed workforce, with each of the top locations, including San Diego, CA, Boulder, CO, and Morrisville, NC, housing one employee each. The 'Other' category accounts for a significant portion of the workforce, suggesting a flexible remote work strategy that allows for broader geographic diversity while still supporting a centralized operational hub.
